+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

C

Actively Recruiting

This research aims to compare two approaches for treating previously untreated amblyopia in children aged 3 to under 13 years. It evaluates whether using glasses and patching at the same time leads to similar improvements in vision as first using glasses alone, followed by patching only if needed. The trial focuses on children with amblyopia caused by differences in eye alignment or prescription errors. Children will be assigned randomly to one of two treatment groups one group will wear glasses full-time and add patching for 2 hours daily only if there is no improvement after glasses alone the other group will wear glasses and patch the weaker eye for 2 hours daily at the same time from the start. Vision tests will be done at baseline and follow-up visits every 8 weeks for up to 56 weeks. Participants will have their distance visual acuity measured with trial frames before and after getting their glasses to confirm eligibility. During the study, vision will be monitored to classify improvement or stability, guiding whether patching is needed in the sequential group. Outcomes include changes in vision clarity after 56 weeks and quality-of-life assessments. Regular visits help track progress and safety until study completion.

Age: 3Years - 13YearsAll GendersPhase 3
68 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal conjugate vaccine called PG4 in adults aged 18 to 49 years. The study compares three different production lots of the PG4 vaccine to each other and to an existing 20-valent pneumococcal conjugate vaccine 20vPnC to confirm consistent vaccine performance and safety. Participants are randomly assigned to one of four groups three groups receive one of the three different lots of the PG4 vaccine, and the fourth group receives the 20vPnC vaccine. Each participant receives a single injection of their assigned vaccine in the arm. The study uses a randomized, double-blind design with groups allocated in a 2221 ratio to ensure balanced comparison. During the approximately six-month study participation, blood samples are collected to measure immune responses and monitor safety. Researchers assess local and systemic reactions within one week after vaccination, adverse events up to one month, and serious adverse events up to six months. They also analyze specific antibody levels and immune activity to evaluate how the vaccines stimulate the bodys defenses against pneumococcal disease.

Age: 18Years - 49YearsAll GendersPhase 3
37 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of several mRNA-based influenza vaccines in healthy adults aged 18 years and older. This Phase 2, randomized, double-blind study compares six investigational mRNA flu vaccines against licensed influenza vaccines. The goal is to understand how well these vaccines stimulate the bodys defense against the flu virus and to monitor any side effects. Participants will receive one single dose of either one of the six mRNA influenza vaccine candidates or one of the licensed flu vaccines by intramuscular injection on Day 1. The study includes one treatment period where the vaccines are administered, and the participants will be monitored for reactions and immune responses over time. Participants will visit the study site at least three times over approximately six months. At each visit, blood samples will be collected to measure antibody levels, and a nasal swab will be taken at the first visit. Researchers will track local and systemic reactions within 7 days of vaccination, as well as adverse events, serious adverse events, and any new chronic medical conditions for up to six months. The study aims to assess the immune response and safety profile of the vaccines during this period.

Age: 18Years +All GendersPhase 2
15 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and immune response to the RSVpreF vaccine in healthy adults aged 60 years and older. This study includes participants from China and the United States, comparing reactions and antibody responses between those receiving RSVpreF and a placebo in China, while all participants in the US receive RSVpreF. The goal is to understand the effects and immune protection that the vaccine may provide to older adults. Participants will receive a single dose of either the RSVpreF vaccine or placebo in China or only RSVpreF in the US. The study includes a screening visit, followed by vaccination at Visit 1. Subsequent follow-ups include a telephone or clinic visit one week later to assess local and systemic reactions, a clinic visit one month after vaccination for health checks and blood tests, and a final telephone or clinic visit six months after vaccination to monitor overall health. Throughout the study, participants will have blood tests at screening China only, on vaccination day, and one month post-vaccination to measure antibody levels. Researchers will monitor local injection site reactions, systemic symptoms, adverse events, and newly diagnosed chronic medical conditions for up to six months. Participants will be involved in electronic diary recording and regular follow-up visits during the approximately six-month participation period.

Age: 60Years +All GendersPhase 3
15 locations
W

Actively Recruiting

This research aims to evaluate a 12-week exercise program designed for adults with primary antibody deficiency disorders. The study focuses on determining if this exercise program is safe, practical, and acceptable for participants, while also assessing its potential to improve quality of life and enhance immune system function. Participants will engage in a structured, moderate-intensity exercise program delivered through a mobile application over 12 weeks. Throughout the study, exercise activity will be tracked via the app, and participants will complete health questionnaires. Blood samples will be collected during patient visits to monitor immune-related markers. Assessments will be conducted at the start and end of the program to evaluate progress and adherence. During the study, participants will report any symptoms or infections experienced. Researchers will measure recruitment and retention rates, app usage frequency, workout durations, perceived exertion levels, and data completeness. These outcomes will help assess the acceptability and effectiveness of the exercise intervention. The total participation spans 12 weeks, with continuous monitoring through the mobile application and scheduled patient visits.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
2 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
C

Actively Recruiting

Researchers are evaluating and comparing two treatments for patients with treatment-resistant depression TRD intravenous racemic ketamine and intranasal Esketamine Spravato4. This study aims to assess how effective each treatment is at reducing depression symptoms, how acceptable they are to patients, and how well patients tolerate any side effects. The study also explores factors that might predict which treatment works better for certain individuals. It is a randomized, multi-site, phase 3 comparative effectiveness trial enrolling about 400 adult participants. Participants will be randomly assigned to receive either racemic ketamine or Esketamine Spravato. Racemic ketamine will be administered intravenously over 40 minutes with a maximum dose of 60 mg per day and a lifetime limit of 8 doses. Esketamine will be given as a nasal spray with doses ranging from 56 to 84 mg, with allowances to reduce to 28 mg if needed for tolerance. The treatment period spans 4 weeks with dosing sessions following FDA guidelines. Throughout the study, participants will be monitored regularly for changes in their depression symptoms using self-reported and clinician assessments. Researchers will evaluate response, remission, suicidal ideation, disability level, quality of life, healthcare use, acceptability, global severity, improvement, tolerability, and safety over the treatment period. The primary outcome is self-reported effectiveness at 30 days. Participants will be followed for the duration of the trial, which lasts up to 5 years in total.

Age: 18Years +All GendersPhase 3
8 locations
R

Actively Recruiting

Researchers are evaluating the Portable Rehabilitation Interface PoRI device to improve hand motor function in patients recovering from a stroke. This clinical trial compares the use of the PoRI device combined with conventional hand therapy versus conventional therapy alone for post-stroke hand rehabilitation. The study aims to assess the devices impact on hand function and pain in individuals who have experienced a stroke recently. Participants in the experimental group will receive seven 20-minute sessions with the PoRI device over 10 days, alongside one hour of conventional therapy five days a week for two to three weeks. The control group will receive only the conventional therapy for the same duration and frequency. The PoRI device is a handheld tool designed to assist movement in the hand for patients with sensorimotor hand dysfunction. During the study, participants will be assessed using several measures including the Fugl-Meyer Assessment, Box-and-Block Test, Visual Analog Scale for pain, Short Form McGill Pain Questionnaire, and Modified Ashworth Scale at baseline and after two to three weeks. Researchers will also evaluate device usability and accessibility through a survey. The total participation period spans approximately two to three weeks of therapy sessions with ongoing monitoring of hand function and pain levels.

Age: 18Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

This research aims to evaluate whether the online program and web-based platform called SCI & U can support people with spinal cord injury SCI as they transition from hospital to community living. The study focuses on individuals within three years of their SCI who are either planning to be discharged to or currently living in the community in British Columbia, Canada, or Connecticut, United States. The main question is whether this program can reduce emotional distress and improve self-management skills and confidence compared to usual peer support. Participants will be randomly assigned to either the SCI & U self-management program or a control group receiving the existing peer support program. Those in the SCI & U group will take part in up to 14 online coaching sessions with trained peer health coaches. These sessions, lasting about 45 to 60 minutes each, will cover health topics like bladder, bowel, skin care, pain, healthy eating, and mental health, along with self-management skills such as goal setting and problem solving. The control group will receive standard peer support services. During the study, participants will complete surveys at the start, 6 months, and 12 months to measure emotional distress, self-efficacy, health activities, social support, and other health-related outcomes. Coaches will track progress on the web platform, including goal setting and action plans. The research team will closely monitor these measures to understand the programs impact on health self-management and secondary complications over time.

Age: 18Years +All GendersPhase Not Applicable
2 locations
I

Actively Recruiting

Researchers are evaluating whether using RECELL4 Autologous Skin Cell Suspension ASCS with de-epithelialized tissue provides better skin color matching than standard grafting techniques in patients undergoing head and neck reconstruction. This study aims to compare color match, healing, and patient satisfaction across three reconstruction methods for cutaneous defects in the head and neck region. Participants will have their wound divided into three sections to receive different treatments split-thickness skin graft, de-epithelialized tissue alone, and de-epithelialized tissue combined with RECELL4 ASCS. The intervention is applied on the day of surgery, with all participants receiving the same combined treatment and serving as their own controls. The study compares these methods to see which provides better color matching. After surgery, participants will return for follow-up visits on Day 14 and at 1, 3, and 6 months. During these visits, researchers will measure skin color matching using a handheld colorimeter, assess wound healing and morbidity, collect patient satisfaction data through questionnaires, and monitor for any adverse events. The study tracks outcomes over six months to evaluate the success of the reconstruction methods.

Age: 18Years +All GendersPhase Not Applicable
3 locations

1-10 of 11

1